A meta-analysis of 19 studies found that pediatric patients with hidradenitis suppurativa (HS) show an increased rate of ...

The assessment of Crohn's disease activity through endoscopy is a cornerstone of both clinical management and research. In The Lancet Gastroenterology & Hepatology, Christopher Ma and colleagues ...

SEOUL, June 9 (Yonhap) -- South Korean chip giant SK hynix Inc. ranked first in operating profit among 1,000 major listed ...

Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. Leveraging ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

South Korea’s biosimilar maker Celltrion Inc. will venture into the contract development and manufacturing organization (CDMO) market, the company said on Monday, citing its founder and Chairman Seo ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerate its transformation into an original drug developer.

Celltrion announced a plan for a free capital increase, and on the 26th, the stock price is showing an upward trend in the After-Market (3:40 p.m. to 8 p.m.). Celltrion's stock was traded at ...

INCHEON, South Korea, May 24, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for YUFLYMA ® ...